Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Merck & Co. Pays Endocyte $120M for Phase III Folate Receptor-Targeting Anticancer Drug

Small molecule drug conjugate could be submitted for first EU approval against platinum-resistant ovarian cancer by year end.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll